Gangtok Chronicle

Limb-Girdle Muscular Dystrophy (LGMD) Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – aTyr Pharma, PTC Therapeutics, Sarepta Therapeutics, and Others

 Breaking News
  • No posts were found

Limb-Girdle Muscular Dystrophy (LGMD) Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – aTyr Pharma, PTC Therapeutics, Sarepta Therapeutics, and Others

August 16
17:40 2022
Limb-Girdle Muscular Dystrophy (LGMD) Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies - aTyr Pharma, PTC Therapeutics, Sarepta Therapeutics, and Others
Delveinsight Business Research LLP
Limb-Girdle Muscular Dystrophy (LGMD) market size is anticipated to increase for the study period owing to the rise in the number of Prevalent cases of Limb-Girdle Muscular Dystrophy patients in 7MM, the disease awareness, and promising emerging pipeline therapies. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Limb-Girdle Muscular Dystrophy.

DelveInsight’s “Limb-Girdle Muscular Dystrophy (LGMD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Limb-Girdle Muscular Dystrophy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Limb-Girdle Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Limb-Girdle Muscular Dystrophy Market

Limb-Girdle Muscular Dystrophy (LGMD): An Overview

Limb-girdle muscular dystrophy (LGMD) is a term for a group of diseases that cause weakness and wasting of the muscles in the arms and legs. The muscles most affected are those closest to the body (proximal muscles), specifically the muscles of the shoulders, upper arms, pelvic area, and thighs.

The different subtypes of LGMD can be broadly categorized under two inheritance patterns, autosomal dominant and autosomal recessive. Autosomal means that the genes involved are present on the autosomes or non-sex chromosomes, the X and the Y chromosome. So both males and females have the same probability of developing the disease.

Even though many genes that cause LGMD have been identified, other genes that are thought to be involved in rarer forms of LGMD have yet to be identified.

Limb-Girdle Muscular Dystrophy (LGMD) Market Key Facts

  • According to the National Institutes of Health, it is difficult to determine the prevalence of limb-girdle muscular dystrophy because its features vary and overlap with those of other muscle disorders. Prevalence estimates range from 1 in 14,500 to 1 in 123,000 individuals.

  • According to the National Organization for Rare Disorders, the incidence of the disorder is unknown. The relative frequencies of the different types of LGMD vary from population to population, but worldwide LGMD2G, 2H and 2J are extremely rare.
  • As per the Orphanet, the estimated prevalence for all forms of LGMD ranges from 1/44,000 to 1/123,000.

Limb-Girdle Muscular Dystrophy (LGMD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Limb-Girdle Muscular Dystrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Limb-Girdle Muscular Dystrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Segmentation

  • Prevalent cases of Limb-Girdle Muscular Dystrophy

  • Type-specific Prevalent Cases of Limb-Girdle Muscular Dystrophy

  • Severity-specific Prevalent Cases of Limb-Girdle Muscular Dystrophy

  • Diagnosed and Treatable Cases of Limb-Girdle Muscular Dystrophy

Limb-Girdle Muscular Dystrophy (LGMD) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Limb-Girdle Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Limb-Girdle Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Limb-Girdle Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market

Limb-Girdle Muscular Dystrophy (LGMD) Therapeutics Analysis

The current pipeline for Limb-Girdle Muscular Dystrophy does not hold many significant products, it has very few products that certain key players are developing. However, the dynamics of the Limb-Girdle Muscular Dystrophy market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies.

Some of the key companies in the Limb-Girdle Muscular Dystrophy (LGMD) Market include:

  • aTyr Pharma, Inc.

  • PTC Therapeutics

  • Sarepta Therapeutics, Inc.

And many others

Limb-Girdle Muscular Dystrophy (LGMD) Therapies covered in the report:

  • Deflazacort

  • SRP-9003

  • ATYR1940

And many more. 

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Limb-Girdle Muscular Dystrophy Competitive Intelligence Analysis

4. Limb-Girdle Muscular Dystrophy Market Overview at a Glance

5. Limb-Girdle Muscular Dystrophy Disease Background and Overview

6. Limb-Girdle Muscular Dystrophy Patient Journey

7. Limb-Girdle Muscular Dystrophy Epidemiology and Patient Population

8. Limb-Girdle Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Limb-Girdle Muscular Dystrophy Unmet Needs

10. Key Endpoints of Limb-Girdle Muscular Dystrophy Treatment

11. Limb-Girdle Muscular Dystrophy Marketed Products

12. Limb-Girdle Muscular Dystrophy Emerging Therapies

13. Limb-Girdle Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Limb-Girdle Muscular Dystrophy Market Outlook (7 major markets)

16. Limb-Girdle Muscular Dystrophy Access and Reimbursement Overview

17. KOL Views on the Limb-Girdle Muscular Dystrophy Market.

18. Limb-Girdle Muscular Dystrophy Market Drivers

19. Limb-Girdle Muscular Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Report by DelveInsight

Hematuria Market
“Hematuria Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Hematuria Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Hematuria therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/